Furthermore, transforming growth factor beta (TGF-β) secreted by Tregs induces EMT, indicating that the use of a TGF-β inhibitor contributes to the sensitivity of HCC cells to sorafenib and regorafenib [146]. Here, TGFB1 is linked to hepatocellular carcinoma.